Praxis Precision Medicines Inc Quick Ratio (PRAX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Praxis Precision Medicines Inc   (NASDAQ: PRAX)

Praxis Precision Medicines Inc 's Quick Ratio

PRAX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 14.2 above Praxis Precision Medicines Inc average.

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Quick Ratio than Praxis Precision Medicines Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 98, from total ranking in the second quarter 2026 at 196.

Explain Quick Ratio?
How much Cash & cash equivalents PRAX´s has?
What are PRAX´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PRAX/financial-strength
https://api.csimarket.com/api/v1/companies/PRAX/fundamentals
https://api.csimarket.com/api/v1/companies/PRAX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
PRAX Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 0.1 %
Y / Y Cash & cash equivalent Change 178.98 %
Quick Ratio MRQ 14.2
PRAX's Total Ranking # 98
Seq. Current Liabilities Change 7.01 %
Seq. Cash & cash equivalent Change -55.74 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 17
Overall Market # 98


Quick Ratio Statistics
High Average Low
34.32 10.74 2.87
(Jun 30 2026)   (Mar 31 2023)




Financial Statements
Praxis Precision Medicines Inc 's Current Liabilities $ 52 Millions Visit PRAX's Balance sheet
Praxis Precision Medicines Inc 's Cash & cash equivalent $ 745 Millions Visit PRAX's Balance sheet
Source of PRAX's Sales Visit PRAX's Sales by Geography


Cumulative Praxis Precision Medicines Inc 's Quick Ratio

PRAX's Quick Ratio for the trailling 12 Months

PRAX Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 19.98 %
Y / Y Cash & cash equivalent TTM Growth 195.99 %
Quick Ratio TTM 18.17
Total Ranking TTM # 3080
Seq. Current Liabilities TTM Growth 0.02 %
Seq. Cash & cash equivalent TTM Growth 14.33 %


On the trailing twelve months basis PRAX Cash & cash equivalent more than doubled by 178.98 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Praxis Precision Medicines Inc 's Quick Ratio to 18.17, above PRAX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 412 other companies have achieved higher Quick Ratio than Praxis Precision Medicines Inc . While Quick Ratio overall ranking has improved so far to 3080, from total ranking during the twelve months ending second quarter 2026 at 3316.

Explain Quick Ratio?
How much Cash & cash equivalents PRAX´s has?
What are PRAX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 413
Healthcare Sector # 821
Within the Market # 3080


trailing twelve months Quick Ratio Statistics
High Average Low
18.36 9.03 3.61
(Jun 30 2021)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Alto Neuroscience Inc   17.90 $ 319.344  Millions$ 17.836  Millions
Upstream Bio Inc   17.34 $ 207.365  Millions$ 11.960  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Arrivent Biopharma inc   16.86 $ 393.691  Millions$ 23.357  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Whitehawk Therapeutics Inc   16.25 $ 169.672  Millions$ 10.441  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions

Date modified: 2026-11-10T05:32:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.